Navigation Links
Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical
Date:11/30/2009

SHENZHEN, China, Nov. 30 /PRNewswire-FirstCall/ - Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India. This contract promises additional increase in revenues for Hard to Treat Diseases in the following quarters.

The contract between HTDS and the Indian company secures the supply of raw pharmaceutical material to the Indian pharmaceutical company in the range of about 1 million USD. Mellow Hope will be ready to release the shipments shortly. This contract is bound to strengthen Mellow Hope's sales and further increase the value of HTDS.

HTDS' CEO Terry Yuan said, "With our earlier, 4 million USD deal with Indian Hetero Ltd. and our H1N1 vaccine deal with Chile, this is another great news for HTDS. Our business has truly grown in past few months and the investors must appreciate our achievements. With the world growing smaller and smaller, the vaccination market and industry are bound to grow bigger. That's the global trend, and HTDS is definitely a part of it."

Hard to Treat Diseases (HTDS) is also a parent company with operations in Serbia based Slavica Biochem www.slavicabiochem.com. This company focuses on the enhancement and modification of existing and approved medications as well as on cancer research. The MindUp cancer research http://www.mindupbioresearch.com has been delivering groundbreaking results on the international level. The company expects to make some significant news announcement with a separate unrelated pharmaceutical company on this shortly.

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters,www.minamargroup.com

SOURCE Hard to Treat Diseases


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Parent training key to improved treatment of behavior problems in children with autism
2. Tailor-made HIV/AIDS treatment closer to reality
3. Natural Soy Component May Help Treat Colon Cancer
4. Cetuximab Helps Treat Colorectal Cancer
5. One Step Closer to New Diabetes Treatment
6. Novel Technology in Treating Chronic Sinus Infections Available at Baptist
7. Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain
8. Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger
9. Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment
10. Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery
11. Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
Breaking Medicine Technology: